Odyssey Therapeutics, Inc. - 10-Q Filing

Odyssey Therapeutics reports Q3 financial results featuring significant R&D and G&A expenses alongside complex contingent consideration valuations.

SEC EDGAR ·

Tickers: $ODTX

Read the full article at SEC EDGAR

More Regulatory news